PCOS Treatment Availability: Hospital Pharmacy Reference
PCOS treatment classes used in India, prevalence data, generic availability, and what reliable hospital pharmacy stocking of PCOS therapy requires.
This covers the drug classes actually used to treat PCOS per current international and Indian evidence, what the prevalence data says about the scale of demand, and what that means for how a hospital pharmacy should stock for it.
What drug classes treat PCOS, and what does the evidence support?
Combined oral contraceptive pills are the first-line pharmacological treatment for the menstrual irregularity and hyperandrogenism features of PCOS under the 2023 International Evidence-based Guideline. No single preparation is specifically preferred, though guidance favours lower ethinyl estradiol doses and fewer side effects. Metformin is recommended primarily for PCOS's metabolic features, insulin resistance in particular, and the same guideline notes it outperforms inositol-based supplements for that purpose.
Myo-inositol and D-chiro-inositol combinations have shown clinical effectiveness in Indian-specific research, with one multi-centre Indian study following women aged 12–45 diagnosed with PCOS on a 550:150 mg inositol combination and reporting meaningful improvement in PCOS-related outcomes. A 2025 systematic review and meta-analysis of pharmacological and non-pharmacological interventions specifically in Indian women found evidence supporting both approaches, used according to whether the metabolic or reproductive features are the primary treatment target.
How common is PCOS in India, and why does the range vary so widely?
Regional Indian studies report PCOS prevalence ranging from 3.7% to 22.5%, a spread far wider than the roughly 5–10% typically reported in developed countries and 5–30% reported in the United States. This wide Indian range reflects differences in diagnostic criteria, population studied, and screening methodology across individual regional studies rather than a genuinely fivefold difference in underlying disease burden.
ICMR's own dedicated PCOS study was specifically designed to address this gap, aiming to establish accurate national prevalence data along with regional phenotypic variation, comorbidities and risk factors, rather than continuing to rely on the fragmented regional estimates that currently produce such a wide range.
What does Jan Aushadhi generic pricing look like for PCOS treatment?
Metformin hydrochloride prolonged-release 500 mg tablets are listed on the Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) generic schedule at approximately ₹8.85 per unit. That is a fraction of typical branded retail pricing for the same metabolic-therapy component of PCOS treatment. PMBJP covers more than 2,110 generic medicines across over 16,900 Jan Aushadhi Kendras nationwide, with generic pricing generally 50–80% below leading branded equivalents.
Combined oral contraceptive formulations and metformin are both widely represented in India's generic pharmaceutical market, which is a genuine access advantage for a condition that, given the prevalence data above, may affect a meaningful share of any hospital's reproductive-age female patient population.
Does PCOS treatment stop at oral contraceptives and metformin?
No. Anti-androgen agents such as spironolactone are used for persistent hirsutism or acne when oral contraceptives alone don't adequately control androgenic symptoms, and ovulation-induction agents like letrozole are used specifically for women pursuing pregnancy, a distinct treatment goal from menstrual or metabolic management. These represent a third and fourth treatment arm beyond the two most commonly discussed.
The 2023 International Evidence-based Guideline treats fertility management as a separate clinical pathway from routine PCOS symptom control, which means a hospital's obstetrics and gynaecology and fertility services may draw on a wider medicine list than the standard contraceptive-and-metformin combination covers. A pharmacy stocking only for the two most common therapies risks missing this smaller but clinically important demand.
What should a hospital pharmacy stock for PCOS treatment?
A hospital pharmacy serving a reproductive-age female patient population needs both a combined oral contraceptive option and metformin reliably stocked, since current guidance treats these as addressing distinct symptom clusters, reproductive versus metabolic, rather than one substituting for the other. Given how wide India's own prevalence estimates run, a hospital's actual PCOS-related prescription volume is worth tracking locally rather than assumed from a single national figure.
When a hospital's own pharmacy doesn't reliably stock the specific oral contraceptive formulation or metformin release profile a gynaecologist or endocrinologist has prescribed, a patient on a condition that typically needs months of consistent therapy either goes without a dose or sources it externally and may not return for the follow-up visits PCOS management requires. A managed or in-house pharmacy that stocks both treatment arms reliably, alongside affordable generic options, keeps that continuity of care and the prescription inside the hospital. Medyzen's guides on managed hospital pharmacy services and prescription leakage and hospital revenue loss cover this stocking-continuity problem in more depth, and the branded versus generic medicine margins guide covers the cost trade-off between branded and generic options for chronic therapies like this one.
Sources
- 1Evaluation of the Prevalence, Regional Phenotypic Variation... Proposal for the ICMR–PCOS Study — PMC, National Institutes of Health, Indian Council of Medical Research
- 2Pharmacological and Non-Pharmacological Interventions for Polycystic Ovary Syndrome (PCOS) in Indian Women: A Systematic Review and Meta-Analysis — PMC, National Institutes of Health
- 3Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome — Journal of Clinical Endocrinology & Metabolism
- 4Management of polycystic ovary syndrome among Indian women using myo-inositol and D-chiro-inositol — PMC, National Institutes of Health
- 5Pradhan Mantri Bhartiya Janaushadhi Pariyojana — Department of Pharmaceuticals, Government of India
This article is for informational purposes and is not a substitute for professional medical advice. PCOS treatment should be individualised by a treating gynaecologist or endocrinologist based on clinical and metabolic assessment.
FAQ
Frequently asked questions
Under the 2023 International Evidence-based Guideline, combined oral contraceptive pills are first-line for menstrual irregularity and hyperandrogenism, while metformin is recommended primarily for the metabolic features of PCOS, particularly insulin resistance, rather than as a universal first choice for every symptom.
Published regional Indian studies report a wide prevalence range of 3.7% to 22.5%, reflecting differences in diagnostic criteria and study methodology. ICMR launched its own dedicated ICMR-PCOS study specifically to establish more accurate, standardised national prevalence data.
Indian-specific research on myo-inositol and D-chiro-inositol combinations has shown clinical effectiveness for PCOS management, though international guideline evidence notes metformin has greater efficacy than inositol-based options specifically for metabolic features.
Metformin hydrochloride prolonged-release 500 mg is listed under the Jan Aushadhi generic scheme at approximately ₹8.85 per unit, substantially below typical branded pricing, reflecting the scheme's broader 50–80% discount against leading brands.
PCOS treatment, whether hormonal or metabolic, typically requires months of consistent therapy to show benefit. Inconsistent access to the prescribed formulation risks treatment gaps, discontinuation, and patients missing the follow-up visits PCOS management depends on.
Dr. Ananya DeshpandeMBBS, DM (Endocrinology)
Consultant Endocrinologist
Dr. Ananya Deshpande is a consultant endocrinologist writing on diabetes and insulin therapy, thyroid disorders, GLP-1 agonists, and metabolic conditions.